17.14
+0.22(+1.30%)
Currency In USD
| Previous Close | 16.92 |
| Open | 16.98 |
| Day High | 17.47 |
| Day Low | 16.87 |
| 52-Week High | 28.09 |
| 52-Week Low | 7.8 |
| Volume | 636,291 |
| Average Volume | 503,431 |
| Market Cap | 935.19M |
| PE | -3.68 |
| EPS | -4.66 |
| Moving Average 50 Days | 13.84 |
| Moving Average 200 Days | 12.52 |
| Change | 0.22 |
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
GlobeNewswire Inc.
Oct 13, 2025 11:30 AM GMT
Designation supported by results from multiple dose cohorts from the Phase 1/1b trial of ficerafusp alfa in 1L HPV-negative R/M HNSCCBOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutic
Bicara Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 27, 2025 8:01 PM GMT
BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that management
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
Jun 03, 2025 8:01 PM GMT
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that members of